Based on the Indivior PLC Ordinary Shares stock forecast from 2 analysts, the average analyst target price for Indivior PLC Ordinary Shares is USD 19.80 over the next 12 months. Indivior PLC Ordinary Shares’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Indivior PLC Ordinary Shares is Neutral, which is based on 7 positive signals and 7 negative signals. At the last closing, Indivior PLC Ordinary Shares’s stock price was USD 12.38. Indivior PLC Ordinary Shares’s stock price has changed by +6.17% over the past week, +9.27% over the past month and -21.47% over the last year.
No recent analyst target price found for Indivior PLC Ordinary Shares
No recent average analyst rating found for Indivior PLC Ordinary Shares
Company Overview Indivior PLC Ordinary Shares
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. Read Less
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company d...Read More
Frequently Asked Questions About Indivior PLC Ordinary Shares (INDV) Stock
Based on ratings from 2 analysts Indivior PLC Ordinary Shares's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on INDV's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for INDV is USD 19.80 over the next 12 months. The maximum analyst target price is USD 24 while the minimum anlayst target price is USD 15.
INDV stock's Price/Earning ratio is 412.25.
Our analysis grades INDV stock's Price / Earning ratio at F. This means that INDV stock's Price/Earning ratio is above 95% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this INDV may be a overvalued for its sector.
The last closing price of INDV's stock was USD 12.38.
The most recent market capitalization for INDV is USD 1.51B.
Based on targets from 2 analysts, the average taret price for INDV is projected at USD 19.80 over the next 12 months.
This means that INDV's stock price may go up by +59.94% over the next 12 months.
We can't find any ETFs which contains Indivior PLC Ordinary Shares's stock.
As per our most recent records Indivior PLC Ordinary Shares has 1,000 Employees.
Indivior PLC Ordinary Shares's registered address is 10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235.
You can get more information about it from Indivior PLC Ordinary Shares's website at https://www.indivior.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Indivior PLC Ordinary Shares (INDV) Stock
Based on ratings from 2 analysts Indivior PLC Ordinary Shares's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on INDV's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for INDV is USD 19.80 over the next 12 months. The maximum analyst target price is USD 24 while the minimum anlayst target price is USD 15.
INDV stock's Price/Earning ratio is 412.25.
Our analysis grades INDV stock's Price / Earning ratio at F. This means that INDV stock's Price/Earning ratio is above 95% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this INDV may be a overvalued for its sector.
The last closing price of INDV's stock was USD 12.38.
The most recent market capitalization for INDV is USD 1.51B.
Based on targets from 2 analysts, the average taret price for INDV is projected at USD 19.80 over the next 12 months.
This means that INDV's stock price may go up by +59.94% over the next 12 months.
We can't find any ETFs which contains Indivior PLC Ordinary Shares's stock.
As per our most recent records Indivior PLC Ordinary Shares has 1,000 Employees.
Indivior PLC Ordinary Shares's registered address is 10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235.
You can get more information about it from Indivior PLC Ordinary Shares's website at https://www.indivior.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for INDV !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
